- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Fieldview Capital Boosts Bristol Myers Squibb Stake
Investment firm increases position in pharmaceutical company by 375%
Published on Mar. 9, 2026
Got story updates? Submit your updates here. ›
Fieldview Capital Management LLC has significantly increased its stake in Bristol Myers Squibb Company, lifting its holdings by 375.3% in the third quarter according to a recent SEC filing. The investment firm now owns 58,695 shares of the biopharmaceutical company's stock, valued at $2.65 million.
Why it matters
This move by Fieldview Capital suggests the firm sees strong potential in Bristol Myers Squibb, one of the leading pharmaceutical companies focused on oncology, hematology, immunology, and other specialty areas. The increased investment could signal confidence in the company's pipeline and future growth prospects.
The details
Fieldview Capital Management acquired an additional 46,347 shares of Bristol Myers Squibb in the third quarter, bringing its total holdings to 58,695 shares. The firm's position was previously valued at $2.65 million. Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases.
- Fieldview Capital Management filed its Q3 2026 Form 13F with the SEC on March 9, 2026.
The players
Fieldview Capital Management LLC
An investment management firm that has significantly increased its stake in Bristol Myers Squibb.
Bristol Myers Squibb Company
A global biopharmaceutical company focused on developing and delivering medicines for serious diseases, with a strong emphasis on oncology, hematology, immunology, and specialty areas.
The takeaway
Fieldview Capital's substantial increase in its Bristol Myers Squibb holdings suggests the firm sees significant upside potential in the pharmaceutical company's future. This move underscores the investment community's confidence in Bristol Myers Squibb's ability to continue delivering innovative therapies and driving growth.
